FIZE Medical announced on July 27, 2026, that its FIZE kUO automated urine output monitoring system had received CE marking and UKCA certification, allowing the company to begin commercial distribution across European markets and Great Britain. The privately held medical technology company said it had prepared local-language interfaces and established distributor relationships to support the launch.
The development removes two important regulatory barriers, but it should not be interpreted as evidence that the device improves clinical outcomes or will be adopted rapidly by hospitals. FIZE kUO is a bedside monitoring system intended to automate the measurement and documentation of urine output in catheterised patients, an area of intensive care that often still depends on nurses manually reading collection chambers and entering hourly figures into clinical records.
FIZE Medical is therefore moving from a regulatory expansion story into a hospital execution story. European intensive care units will need to determine whether the platform produces sufficiently reliable data, reduces documentation burden, integrates with existing electronic medical records and justifies the cost of its bedside equipment and single-use consumables.
What do the CE marking and UKCA certification permit FIZE Medical to do?
CE marking indicates that FIZE kUO has been assessed for conformity with the applicable European medical device requirements for its specified intended use. It is not equivalent to United States-style regulatory approval, nor does it demonstrate that the system is clinically superior to manual urinometers or competing automated devices.
FIZE Medical’s announcement did not identify the device classification, the notified body involved, the certificate number or the precise wording of the European certified intended purpose. It also did not disclose whether separate configurations, software functions or paediatric applications fall within the same certification. Those details will matter to hospital regulatory teams reviewing the product for procurement.
The publicly available FIZE kUO operator manual describes the system as intended for urine drainage and renal function assessment in hospitals and healthcare facilities under the supervision of trained professionals. It states that the device may be used with an indwelling Foley catheter of 6 French or larger, subject to listed contraindications and operating restrictions. The precise European and British labelling should still be checked against the newly issued conformity documentation rather than assumed from an earlier manual.
The UKCA element applies specifically to Great Britain, comprising England, Scotland and Wales. Northern Ireland continues to operate under European medical device rules, where CE marking, or CE plus UKNI marking in certain circumstances, remains relevant. UKCA marking alone is not recognised in Northern Ireland or the European Union.
FIZE Medical’s UKCA route provides a dedicated basis for access to Great Britain, although CE marked devices can currently continue to enter the market under transitional arrangements. Depending on the European legislation used, CE marked general medical devices may remain eligible for placement on the Great Britain market until 2028 or 2030. The Medicines and Healthcare products Regulatory Agency has also consulted on indefinite recognition of devices complying with the European Medical Device Regulation.
That regulatory overlap means UKCA certification may offer FIZE Medical additional long-term certainty and procurement credibility, rather than functioning as the only route through which the company could have entered Great Britain. It also gives hospitals clearer evidence that the manufacturer has prepared for the domestic British framework while policy on permanent CE recognition continues to evolve.
How does FIZE kUO seek to replace manual urine output monitoring in intensive care?
FIZE kUO combines a reusable bedside console with a sterile, single-use disposable kit. The disposable assembly includes tubing, a sensor, a sampling port, a cassette and a urine collection bag, while the console measures urine output, displays trends and can transfer information to hospital systems such as an electronic medical record.
Its practical proposition is relatively straightforward. Instead of asking nursing staff to inspect a collection chamber at prescribed intervals, estimate the volume, record the time and manually enter the result, the system captures urine output continuously and produces time-based trends. Hospitals can configure clinical or operational alerts, while electronic record integration can reduce duplicate documentation.
The potential benefit is not merely a more elegant digital display. Manual urine output records can be affected by late readings, inconsistent timing, transcription errors, accumulated urine within tubing and variation between staff members. Published studies involving other automated urinometers have found improvements in measurement timing, data completeness or agreement with reference measurements, although those findings cannot automatically be transferred to FIZE kUO.
Continuous measurement could also produce a more detailed physiological picture than a single hourly total. A patient producing little urine for most of an hour and then releasing a larger volume near the measurement point may appear similar on an hourly chart to a patient with stable output throughout the period. Higher-frequency data can expose those differences, but clinicians still need validated rules explaining which patterns require intervention.
FIZE kUO does not remove the clinical risks associated with urinary catheterisation, and it should not be understood as an autonomous acute kidney injury diagnostic. It measures urine output in patients who already have an appropriate catheter and supports renal function assessment within a wider clinical evaluation.
The company’s manual states that the system should not be used where bladder integrity may be compromised, including certain reconstructed bladders, urinary diversions and congenital abnormalities involving the bladder or urethra. It also identifies significant bladder blood clots or calculi as contraindications and states that the system is not intended for continuous bladder irrigation.
Is FIZE Medical’s clinical evidence mature enough to support broad adoption claims?
The clinical rationale for more accurate urine output monitoring is credible. Urine output is included in the assessment of acute kidney injury and can provide information about renal function, perfusion and response to fluid or diuretic treatment. The more difficult question is whether continuous automated measurement leads to earlier useful decisions, changes treatment appropriately or improves patient outcomes.
FIZE Medical has generated early performance and observational evidence, but the available package remains less mature than would be required to establish broad outcome benefits. A preliminary 2020 evaluation involving 22 consecutive intensive care patients compared an electronic FIZE urinometer with a conventional manual urinometer and graduated-cylinder measurements. The investigators reported an average deviation of 4 percent, with a standard deviation of 3 percentage points, for the electronic system, compared with 17 percent, with a standard deviation of 23 percentage points, for manual measurement.
That study supports the measurement concept, but its small sample size limits generalisability. An accuracy comparison also does not demonstrate that using the device reduces acute kidney injury, shortens intensive care stays, lowers dialysis use or improves survival.
FIZE Medical subsequently reported interim findings from a retrospective observational analysis using intensive care electronic medical record data. The company said minute-by-minute urine output data could shorten the time required to evaluate response during a furosemide stress assessment, but the disclosure was preliminary and company reported. A complete peer-reviewed dataset, including patient-selection methods, confounding adjustment and full statistical results, was not provided in the announcement.
The company also presented research at the 2026 Society of Critical Care Medicine Congress examining the urine output response during the first 15 minutes after intravenous furosemide. FIZE Medical said greater early urine output was associated with improved 30-day survival in a retrospective adult intensive care population. An association of this kind may have prognostic value, but it does not show that monitoring caused the survival difference or that an intervention based on the measurement would improve outcomes.
A prospective post-market observational study registered as NCT07022314 is expected to enrol 45 adults undergoing coronary artery bypass grafting or valve surgery. The planned study will examine urine output responses to fluids, diuretics and vasopressors in a cardiothoracic intensive care unit, including differences between patients who do and do not develop postoperative acute kidney injury. The registry status was listed as not yet enrolling, meaning the study cannot yet support the European launch with prospective results.
The evidence programme is therefore moving in the right direction, from technical performance towards clinical interpretation, but the crucial utility question remains open. Hospitals will want to know whether the system identifies meaningful deterioration earlier than existing care, how often alerts alter management, whether false alarms increase workload and whether greater data resolution improves outcomes rather than simply creating more data.
Why will distribution, integration and consumable economics determine hospital adoption?
FIZE Medical said it had appointed medical device distributors in key European markets and localised the platform for initial launch countries. However, the company did not name the distributors, identify the first countries, announce purchasing contracts or disclose confirmed hospital installations in Europe or Great Britain.
Those omissions do not diminish the regulatory milestone, but they limit visibility into the speed of the commercial rollout. A distribution agreement can create market coverage, training capacity and local technical support, yet it does not guarantee purchasing commitments from hospitals.
Intensive care technology purchases commonly require review by clinicians, infection-prevention teams, biomedical engineering departments, information technology specialists, cybersecurity teams and procurement committees. FIZE Medical will need to demonstrate not only measurement performance but also reliable electronic medical record integration, data security, device uptime, cleaning procedures, technical support and compatibility with existing catheter and bed-space practices.
The commercial model also appears to include recurring revenue from sterile disposable kits. That can create predictable revenue after installation, but recurring consumable costs may become a central procurement issue. A 2023 systematic review of automated urine measurement technologies identified proprietary disposables, equipment expense, operational complexity and connectivity limitations as recurring barriers to widespread adoption across the category.
FIZE Medical strengthened its financial position in March 2026 when existing investors exercised $6 million of warrants, bringing the company’s stated Series A financing to $36 million. Management said the proceeds would support commercial expansion in the United States, Japan and Europe, additional clinical validation and development of predictive fluid-management capabilities.
That capital provides resources for a multicountry launch, but European commercialisation can consume cash quickly. Each market may require language support, distributor training, post-market surveillance, technical service, data-integration work and clinical education before meaningful recurring sales emerge.
How crowded is the European market for automated urine output monitoring?
FIZE Medical is not introducing the first automated urine monitoring concept into critical care. Published literature and commercial reviews have identified systems including Accuryn, Sippi, Clarity RMS, RenalGuard and other electronic or sensor-based urine monitoring platforms. Accuryn, for example, combines automated urine output monitoring with temperature and, in selected configurations, intra-abdominal pressure measurement.
Competition will therefore focus on practical differentiation rather than the novelty of automation alone. FIZE Medical’s compatibility with standard Foley catheters could be commercially relevant because hospitals may not need to replace the catheter itself with a proprietary sensing catheter. Its electronic medical record connectivity, low-volume monitoring and ability to transfer stored measurement data between consoles may also support workflow continuity.
The counterweight is that hospitals may compare the system against established devices, low-cost manual methods and newer European entrants. Procurement teams will examine the total cost per monitored patient, frequency of disposable replacement, training time, accuracy across different urine characteristics, alarm burden, maintenance requirements and evidence that the platform produces operational savings.
Clinical enthusiasm may be strongest where patients are already catheterised and hourly urine monitoring is considered necessary, including intensive care, major surgery, cardiothoracic care and selected paediatric settings. Expansion beyond those environments will be harder because unnecessary catheterisation cannot be justified merely to obtain continuous urine data.
What must FIZE Medical prove after its European and British launch?
The next meaningful milestones will be measurable commercial and clinical outcomes rather than additional statements about market availability. Named distributor coverage, first hospital installations, repeat disposable orders, integration with major electronic medical record platforms and multicentre evidence would provide clearer indications of adoption.
FIZE Medical will also need to show that continuous urine output data can be converted into actionable clinical protocols. A device may record measurements accurately and still struggle commercially if hospitals lack agreed thresholds, response pathways or confidence that acting on earlier signals improves care.
The CE marking and UKCA certification substantially widen FIZE Medical’s addressable geography and place the company in several of the world’s most developed critical care markets. They do not settle whether FIZE kUO will become routine equipment beside intensive care beds.
That outcome will depend on whether FIZE Medical can turn regulatory conformity into dependable hospital implementation, and whether its growing evidence programme demonstrates clinical utility beyond improved measurement and documentation. Europe is now open to the system. The harder work begins inside the intensive care unit.
